Advertisement

Caspase activity in lymphocytes of patients with depression and anxiety of different severity

  • A. A. Yakovlev
  • T. A. Druzhkova
  • M. N. Grishkina
  • A. B. Guekht
  • N. V. Gulyaeva
Article

Abstract

Although borderline personality disorders (BPD) are most common psychiatric diseases, their pathogenesis still remains poorly understood. According to the literature and results of own previous studies, pathological changes associated with BPD may affect not only brain cells, but also cells of the immune system. One of the functionally important examples of communication between the immune and nervous systems in BPD is death of lymphocytes, particularly recognized in the most common mental disorder, depression. We have shown previously that activity of caspases, the key enzymes of programmed cell death increases in some types of BPD. In this study, we have investigated caspase activity in peripheral blood mononuclear cells (PBMC) of BPD patients of different severity. It has been found that in severe depression activity of initiator and executive caspases decreases as compared with control, and patients with a mild form of depression. In contrast, patients with severe form of anxiety were characterized by increased activity of the same enzymes as compared with control and patients with less severe forms of anxiety. Thus, the study of PBMC caspase can not only discriminate mild and severe forms of BPD, but can also help to identify specific molecular mechanisms responsible for the development of depression and anxiety.

Keywords

depression anxiety lymphocytes apoptosis caspases borderline personality disorders 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Aleksandrovskii, Yu.A., in Pogranichnyie psikhicheskie rasstroistva: klinicheskie i sotsial’nyie aspekty (Borderline Psychiatric Disorders: Fundamental, Clinical, and Social Aspects), Gusev, E.I., Guekht, A.B., Avedisova, A.S., and Gulyaeva, N.V., Eds., Moscow: FCHO, 2014, pp. 23–43.Google Scholar
  2. 2.
    Wray, N.R., Pergadia, M.L., Blackwood, D.H.R., Penninx, B.W.J.H., Gordon, S.D., Nyholt, D.R., et al., Mol. Psychiatry, 2012, vol. 17, pp. 36–48.CrossRefGoogle Scholar
  3. 3.
    Raison, C.L., Capuron, L., and Miller, A.H., Trends Immunology, 2006, vol. 27, pp. 24–31.CrossRefGoogle Scholar
  4. 4.
    Yakovlev, A.A., Neurochem. J., 2015, vol. 32, pp. 1–4.Google Scholar
  5. 5.
    Gladkevich, A., Kauffman, H.F., and Korf, J., Prog. Neuropsychopharmacol. Biol. Psychiatry, 2004, vol. 28, pp. 559–576.CrossRefGoogle Scholar
  6. 6.
    Bei, E., Salpeas, V., Pappa, D., Anagnostara, C., Alevizos, V., and Moutsatsou, P., Psychoneuroendocrinology, 2009, vol. 34, pp. 1162–1175.CrossRefGoogle Scholar
  7. 7.
    Szuster-Ciesielska, A., Slotwinska, M., Stachura, A., Marmurowska-Michalowska, H., Dubas-Slemp, H., Bojarska-Junak, A., et al., Prog. Neuropsychopharmacol. Biol. Psychiatry, 2008, vol. 32, pp. 686–694.CrossRefGoogle Scholar
  8. 8.
    Gerasimovich, E.S., Yakovlev, A.A., Druzhkova, T.A., Grishkina, M.N., Guekht, A.B., and Gulyaeva, N.V., Biomed. Khim., 2016, vol. 62, pp. 89–92.CrossRefGoogle Scholar

Copyright information

© Pleiades Publishing, Ltd. 2017

Authors and Affiliations

  • A. A. Yakovlev
    • 1
    • 2
  • T. A. Druzhkova
    • 2
  • M. N. Grishkina
    • 2
  • A. B. Guekht
    • 2
    • 3
  • N. V. Gulyaeva
    • 1
    • 2
  1. 1.Institute of Higher Nervous Activity and NeurophysiologyRussian Academy of SciencesMoscowRussia
  2. 2.Research and Clinical Center for NeuropsychiatryMoscowRussia
  3. 3.Russian National Research Medical UniversityMoscowRussia

Personalised recommendations